Denali Therapeutics Stock News

Arthur M. Cohen & Associates LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 121.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 7,547 shares of the companys stock after purchasing an additional 4,139 shares during the quarter. Arthur M. Cohen & Associates LLCs holdings in Denali Therapeutics were worth $381,000 []

— Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) —

— Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) —

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given a consensus recommendation of Buy by the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts []

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the companys stock in a transaction that occurred on Wednesday, November 10th. The shares were sold at an average price of $52.81, for a total value of $87,981.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which []

Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th

ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cr

Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases Proven commerc

— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS — — Investigational EIF2B activator approach has potential to be a first-in-class treatment fo

Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities an

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would b

Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali's Transport Vehicle to cross the blood-brain barrier Preclinical studies show enhanced brain uptake of progra